Kiren Kresa-Reahl1, Pavle Repovic2, Derrick Robertson3, Macaulay Okwuokenye4, Leslie Meltzer4, Jason P Mendoza5. 1. Providence Multiple Sclerosis Center, Portland, OR, USA. 2. Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA, USA. 3. USF Multiple Sclerosis Center, Tampa, FL, USA. 4. Biogen, Cambridge, MA, USA. 5. Biogen, Cambridge, MA, USA. Electronic address: jason.mendoza@biogen.com.
Abstract
PURPOSE: The goal of this study was to evaluate clinical outcomes and patient-reported outcomes (PROs) over 12 months in patients with relapsing multiple sclerosis (RMS) who switched from glatiramer acetate (GA) to delayed-release dimethyl fumarate (DMF) 240 mg BID after suboptimal response to GA in real-world clinical practice. METHODS: The RESPOND (Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS) study was a Phase IV, prospective, multicenter, open-label, single-arm, 12-month observational trial. The study was conducted in the United States at 63 sites between August 2013 and February 2016. Patients diagnosed with RMS who experienced a suboptimal response to GA (defined as perceived suboptimal efficacy, intolerance, or poor adherence to GA) were eligible for enrollment. DMF treatment was initiated within 60 days of enrollment. The primary objective was to estimate the annualized relapse rate (ARR) at 12 months based on data collected from medical records and compare it with the 12 months before DMF initiation. Secondary objectives of the study included assessing the change in PRO scores from baseline to 12 months; PROs were recorded before and at 6 and 12 months after DMF initiation. FINDINGS: Of the 318 patients included in the analysis population, 247 (78%) completed treatment. Mean (SD) time on GA treatment before switching to DMF was 51.3 months (49.1 months). The ARR (95% CI) reported for the 12 months before DMF initiation was 0.49 (0.42-0.57) compared with 0.11 (0.07-0.17) at 12 months after DMF initiation, representing a 78% reduction in ARR (P < 0.0001). Statistically significant improvements from baseline were observed for multiple PROs, including the 36-item Short Form Health Survey physical and mental component summaries (P = 0.0201 and P = 0.0014, respectively), the 5-item Modified Fatigue Impact Scale (P = 0.0002), the 14-item Treatment Satisfaction Questionnaire for Medication (P < 0.0001), and the 7-item Beck Depression Inventory (P = 0.0117). IMPLICATIONS: DMF may be an effective treatment option in patients with RMS who experience a suboptimal response to GA. The results should be interpreted with caution due to the observational nature of the study and the lack of a control group. Other limitations of the study include a potential bias due to regression to the mean and lack of randomization. ClinicalTrials.gov identifier: NCT01903291.
PURPOSE: The goal of this study was to evaluate clinical outcomes and patient-reported outcomes (PROs) over 12 months in patients with relapsing multiple sclerosis (RMS) who switched from glatiramer acetate (GA) to delayed-release dimethyl fumarate (DMF) 240 mg BID after suboptimal response to GA in real-world clinical practice. METHODS: The RESPOND (Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS) study was a Phase IV, prospective, multicenter, open-label, single-arm, 12-month observational trial. The study was conducted in the United States at 63 sites between August 2013 and February 2016. Patients diagnosed with RMS who experienced a suboptimal response to GA (defined as perceived suboptimal efficacy, intolerance, or poor adherence to GA) were eligible for enrollment. DMF treatment was initiated within 60 days of enrollment. The primary objective was to estimate the annualized relapse rate (ARR) at 12 months based on data collected from medical records and compare it with the 12 months before DMF initiation. Secondary objectives of the study included assessing the change in PRO scores from baseline to 12 months; PROs were recorded before and at 6 and 12 months after DMF initiation. FINDINGS: Of the 318 patients included in the analysis population, 247 (78%) completed treatment. Mean (SD) time on GA treatment before switching to DMF was 51.3 months (49.1 months). The ARR (95% CI) reported for the 12 months before DMF initiation was 0.49 (0.42-0.57) compared with 0.11 (0.07-0.17) at 12 months after DMF initiation, representing a 78% reduction in ARR (P < 0.0001). Statistically significant improvements from baseline were observed for multiple PROs, including the 36-item Short Form Health Survey physical and mental component summaries (P = 0.0201 and P = 0.0014, respectively), the 5-item Modified Fatigue Impact Scale (P = 0.0002), the 14-item Treatment Satisfaction Questionnaire for Medication (P < 0.0001), and the 7-item Beck Depression Inventory (P = 0.0117). IMPLICATIONS: DMF may be an effective treatment option in patients with RMS who experience a suboptimal response to GA. The results should be interpreted with caution due to the observational nature of the study and the lack of a control group. Other limitations of the study include a potential bias due to regression to the mean and lack of randomization. ClinicalTrials.gov identifier: NCT01903291.
Authors: Amber Salter; Samantha Lancia; Gary Cutter; Robert J Fox; Ruth Ann Marrie; Jason P Mendoza; James B Lewin Journal: Int J MS Care Date: 2021-07-09
Authors: Mark Gudesblatt; Cortnee Roman; Barry A Singer; Hollie Schmidt; Jessica Thomas; Sai L Shankar; Jennifer Lyons; Shivani Kapadia Journal: Adv Ther Date: 2022-05-13 Impact factor: 4.070
Authors: Robert T Naismith; Jerry S Wolinsky; Annette Wundes; Christopher LaGanke; Douglas L Arnold; Dragana Obradovic; Mark S Freedman; Mark Gudesblatt; Tjalf Ziemssen; Boris Kandinov; Ilda Bidollari; Maria Lopez-Bresnahan; Narinder Nangia; David Rezendes; Lili Yang; Hailu Chen; Shifang Liu; Jerome Hanna; Catherine Miller; Richard Leigh-Pemberton Journal: Mult Scler Date: 2019-11-04 Impact factor: 6.312
Authors: Allison Lm Jordan; Jennifer Yang; Caitlyn J Fisher; Michael K Racke; Yang Mao-Draayer Journal: Mult Scler Date: 2020-08-18 Impact factor: 6.312
Authors: Amber Salter; Samantha Lancia; Gary Cutter; Ruth Ann Marrie; Jason P Mendoza; James B Lewin; Robert J Fox Mellen Journal: Ther Adv Neurol Disord Date: 2021-06-30 Impact factor: 6.570
Authors: T Berger; B Brochet; L Brambilla; P S Giacomini; X Montalbán; A Vasco Salgado; R Su; A Bretagne Journal: Mult Scler J Exp Transl Clin Date: 2019-12-02
Authors: Robert T Naismith; Annette Wundes; Tjalf Ziemssen; Elzbieta Jasinska; Mark S Freedman; Anthony J Lembo; Krzysztof Selmaj; Ilda Bidollari; Hailu Chen; Jerome Hanna; Richard Leigh-Pemberton; Maria Lopez-Bresnahan; Jennifer Lyons; Catherine Miller; David Rezendes; Jerry S Wolinsky Journal: CNS Drugs Date: 2020-02 Impact factor: 5.749